Overview
Iambic Therapeutics is a cutting-edge biotechnology company leveraging a sophisticated AI-driven platform to solve the most challenging design problems in drug discovery. By seamlessly integrating accurate, data-efficient physics-based AI technologies with highly automated, high-throughput experimentation, Iambic accelerates the transition from novel molecular designs to actionable biological data on a weekly basis. This closed-loop system allows expert drug hunters to deeply explore chemical spaces, uncover novel mechanisms of action (such as cryptic pockets and allostery), and optimize target product profiles in parallel. The platform is proven to deliver highly differentiated, best-in-class clinical candidates years faster than the industry standard. Iambic’s pipeline currently includes highly selective, brain-penetrant HER2 inhibitors and CDK2/4 therapies designed to bypass dose-limiting toxicities. Additionally, through pioneering multi-modal transformer models like 'Enchant,' Iambic is successfully breaking down the data wall between preclinical and clinical R&D, positioning itself as a transformative partner for major pharmaceutical companies, evidenced by strategic collaborations with partners like Takeda.